Subcutaneous Injections for RA | ACTEMRA® (tocilizumab)
PDF) Long-term treatment with tocilizumab in giant cell arteritis: Efficacy and safety in a monocentric cohort of patients
SJIA Clinical Trial Safety Profile Side Effects | ACTEMRA® (tocilizumab)
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ
Cutaneous Adverse Effects of Surface-Targeted Monoclonal Antibodies – Consult QD
Actemra Side Effects | Common and Rare Reactions to Actemra
TOCILIZUMAB
Hundreds died while taking an arthritis drug, but nobody alerted patients
Practice points for ophthalmologists from the 2020 British Society for Rheumatology Giant Cell Arteritis guidelines | Eye
JCM | Free Full-Text | Steroid-Sparing Effect of Tocilizumab and Methotrexate in Patients with Polymyalgia Rheumatica: A Retrospective Cohort Study
Frontiers | Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review
Tocilizumab in patients with severe COVID-19: a retrospective cohort study - The Lancet Rheumatology
Effect of Tocilizumab on Fatigue and Bone Mineral Density in Patients with Rheumatoid Arthritis
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial - The Lancet Rheumatology
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
Tocilizumab for relapsing and remitting giant cell arteritis: a case series | Journal of Medical Case Reports | Full Text
PDF) Long-term effects of tocilizumab therapy for uveitic macular edema
PJIA Safety Profile Side Effects | ACTEMRA® (tocilizumab)
Frontiers | Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
PDF) Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
Healthcare | Free Full-Text | Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial - The Lancet Rheumatology
Pharmaceutics | Free Full-Text | Safety of Tocilizumab in COVID-19 Patients and Benefit of Single-Dose: The Largest Retrospective Observational Study
Frontiers | Tocilizumab and COVID-19: Timing of Administration and Efficacy
Single Technology Appraisal Tocilizumab for treating giant cell arteritis Committee Papers
